Development of a safer peripheral intravenous cannula (PIVC) with longer indwell duration

Source summary

The challenge asks for a next-generation peripheral intravenous cannula intended to remain in place for at least 10 to 14 days with less thrombophlebitis and infection. Proposed material and design changes cover clot-resistant, hydrophilic, temperature-responsive and biofilm-retarding surfaces, secure body-contoured fixation and compatibility with infused fluids, while remaining cost-effective. The intended settings include intensive and acute care and patients with difficult long-term venous access, such as neonates, chemotherapy recipients and people receiving repeated transfusions; the longer dwell claim requires clinical evidence.